Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8508684 | 0.77 | EPHX1 (0.39) | KMT2AHDAC4HDAC3HDAC7HDAC8 | |
| SCHEMBL6837104 | 0.77 | EPHX1 (0.39) | KMT2AHDAC4HDAC3HDAC7HDAC8 | |
| SCHEMBL8509434 | 0.77 | EPHX1 (0.39) | KMT2AHDAC4HDAC3HDAC7HDAC8 | |
| SCHEMBL8486054 | 0.77 | MEN1 (0.42) | KMT2AMEN1MAN2B1HSD17B2 | |
| SCHEMBL8168467 | 0.77 | EPHX1 (0.39) | KMT2AHDAC4HDAC3HDAC7HDAC8 | |
| SCHEMBL6837215 | 0.77 | EPHX1 (0.39) | KMT2AHDAC4HDAC3HDAC7HDAC8 | |
| SCHEMBL8173575 | 0.77 | EPHX1 (0.39) | KMT2AHDAC4HDAC3HDAC7HDAC8 | |
| SCHEMBL9679048 | 0.77 | EPHX1 (0.39) | KMT2AHDAC4HDAC3HDAC7HDAC8 | |
| (+)Clausenamide SCHEMBL6836959 | 0.76 | HSD17B2 (0.55) | MAN2B1HSD17B2 | |
| (+)Clausenamide SCHEMBL8168700 | 0.76 | HSD17B2 (0.55) | MAN2B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207935-A1 | Novel optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207935-A1 | Novel optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use | HIF1AN, HIF1A, CLN6 | KMT2A 2709/4885TSHR 4724/4885HDAC4 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.